Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.62 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161670 | 1.00 | KMT2A (0.83) | KMT2AMEN1MAPTCACNA1GHTR3A | |
| SCHEMBL2162550 | 0.99 | KMT2A (0.85) | KMT2AMEN1MAPTCACNA1GHTR3A | |
| SCHEMBL2161686 | 0.94 | KMT2A (0.75) | KMT2AMEN1MAPTCACNA1GHTR3A | |
| SCHEMBL2161496 | 0.93 | KMT2A (0.83) | KMT2AMEN1MAPTCACNA1GTP53 | |
| SCHEMBL4701497 | 0.93 | KMT2A (0.83) | KMT2AMEN1MAPTTP53RAD52 | |
| SCHEMBL2171584 | 0.92 | KMT2A (0.82) | KMT2AMEN1MAPTCACNA1GTP53 | |
| SCHEMBL2161642 | 0.92 | KMT2A (0.83) | KMT2AMEN1MAPTTP53RAD52 | |
| SCHEMBL2161514 | 0.91 | KMT2A (1.00) | KMT2AMEN1MAPTHTR3ATP53 | |
| SCHEMBL2162334 | 0.91 | KMT2A (0.74) | KMT2AMEN1MAPTTP53RAD52 | |
| SCHEMBL2162127 | 0.91 | KMT2A (0.84) | KMT2AMEN1MAPTTP53RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985764-B2 | Amide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988076-A1 | AMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | HTR7, HTR2B, NPSR1 | KMT2A 2331/4885MEN1 3828/4885MAPT 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.